Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease

Abstract

This first population pharmacokinetic study of teicoplanin in children with haematological malignancy provided evidence-based support to individualize teicoplanin therapy in this vulnerable population.